Press Releases

News Brief

Samsung Biologics to attend 2025 J.P. Morgan Healthcare Conference


Incheon, S. Korea, Jan 6, 2025 – Samsung Biologics will participate in the 43rd J.P. Morgan Healthcare Conference in San Francisco between January 13-16, 2025.


Samsung Biologics’ CEO and President John Rim will present the company’s achievements and business strategies for the coming year during the main track presentation on January 14.


Samsung Biologics will also meet with investors and potential clients at the Biotech Showcase. The company will mark a new phase of growth at Bio Campus II this year with the completion of Plant 5, bringing up the total capacity to 784,000 liters by April this year. Samsung Biologics also continues to diversify its portfolio, providing end-to-end antibody-drug conjugate (ADC) services at its new dedicated facility.


Incheon, S. Korea, Jan 6, 2025 – Samsung Biologics will participate in the 43rd J.P. Morgan Healthcare Conference in San Francisco between January 13-16, 2025.


Samsung Biologics’ CEO and President John Rim will present the company’s achievements and business strategies for the coming year during the main track presentation on January 14.


Samsung Biologics will also meet with investors and potential clients at the Biotech Showcase. The company will mark a new phase of growth at Bio Campus II this year with the completion of Plant 5, bringing up the total capacity to 784,000 liters by April this year. Samsung Biologics also continues to diversify its portfolio, providing end-to-end antibody-drug conjugate (ADC) services at its new dedicated facility.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION